RecruitingPhase 2NCT05709574

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

Studying NON RARE IN EUROPE: Adenocarcinoma of stomach

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Arizona
Principal Investigator
Junaid Arshad, MD
University of Arizona
Intervention
Tadalafil 20 MG(drug)
Enrollment
10 target
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05709574 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach

← Back to all trials